Motilin Receptor (MLNR)

MA-2029 is a selective, orally active antagonist of the motilin receptor, exhibiting an IC50 of 4.9 nM. It demonstrates high selectivity for the motilin receptor compared to a variety of other receptors and ion channels. This compound is particularly relevant for research into gastrointestinal disorders linked to impaired gastrointestinal motility, providing a valuable tool for studying motility-related pathophysiology and potential therapeutic interventions.

Motilin (26-47), human, porcine is a potent agonist of the motilin receptor, exhibiting a Ki value of 2.3 nM and an EC50 of 0.3 nM in a Chinese hamster ovary cell line. This peptide plays a critical role in gastrointestinal motility and is instrumental in research focused on digestive system disorders and hormone signaling pathways. Its application extends to various studies involving gut motility regulation and the therapeutic potential of motilin-related compounds.

Motilin, canine is a 22-amino acid peptide that acts as a potent agonist of gastrointestinal smooth muscle contraction. This bioactive peptide plays a crucial role in stimulating intestinal motility and has potential applications in gastrointestinal research. It is primarily used to study motility disorders and the regulation of digestive processes in canine models.

KC-11458 is a motilin agonist that enhances gastric motility by stimulating motilin receptors in the gastrointestinal tract. This compound is primarily used for research into gastrointestinal motility disorders and can be valuable in studies investigating the regulation of gastric emptying processes. Its ability to accelerate gastric emptying makes it a potential tool for exploring therapeutic targets in digestive disorders.

EM-523 is a motilin agonist and an erythromycin derivative that selectively targets motilin receptors. It has demonstrated biological activity with pED50 values of 8.19 and 6.08 for inducing contractions in rabbit small intestinal tissue and human duodenal tissue, respectively. This compound is valuable for investigating gastrointestinal diseases and advancing research related to motility disorders.

[Leu13]-Motilin is a motilin analogue that primarily targets motilin receptors. This compound promotes gastrointestinal motility by inducing concentration-dependent contractions in various segments of the gastrointestinal tract, including the gastric antrum, duodenum, jejunum, ileum, and descending colon. [Leu13]-Motilin is utilized in research to explore the mechanisms of gut motility and to investigate potential therapeutic applications in gastrointestinal disorders.

ANQ-11125 is a potent and selective antagonist of motilin, exhibiting a pKd of 8.24. This compound effectively inhibits motilide-induced contractions in vitro in rabbit models, making it a valuable tool for studying gastrointestinal motility and related disorders. ANQ-11125 has potential applications in research focused on gastrointestinal physiology and pharmacology.

Motilin, human, porcine, is a gastrointestinal hormone that plays a critical role in regulating gastrointestinal motility. Released during fasting, eating, and water intake, Motilin enhances enteric cholinergic activity in the human stomach with an EC50 of 33 nM. This biological activity makes it a valuable tool for research into gastrointestinal function and motility disorders.

Mitemcinal fumarate is a selective agonist of the motilin receptor. It demonstrates significant biological activity in promoting defecation and increasing stool bulk without causing excessive diarrhea, as evidenced in preclinical studies in rabbits and dogs. Its rapid onset and short duration of action suggest potential applications in the treatment of constipation, making it a valuable compound for gastrointestinal research.

Mitemcinal is an oral motilin receptor agonist, specifically targeting motilin pathways to enhance gastrointestinal motility. Research demonstrates its capability to promote defecation in animal models, such as rabbits and dogs, without inducing severe diarrhea. Additionally, Mitemcinal increases stool weight while maintaining water content and reduces the latency to first defecation in dogs. This makes Mitemcinal a promising candidate for studies on constipation management and gastrointestinal disorders.

EM574 is a potent agonist of the motilin receptor, demonstrating significant activity in the human gastric antrum and rabbit gastrointestinal tract in vitro. As an erythromycin derivative, EM574 is utilized in research applications exploring gastrointestinal motility and related disorders. Its ability to selectively modulate motilin receptor signaling makes it a valuable tool for advancing studies in gastrointestinal physiology and pharmacology.

[Nle13]-Motilin is a synthetic analog of motilin that functions as a motilin receptor agonist. It effectively stimulates gastrointestinal motility by activating the motilin receptor, making it a valuable tool in studies related to gastrointestinal physiology and potential therapeutics for gut motility disorders. Research applications include investigations into the modulation of gastric emptying and the treatment of gastrointestinal dysmotility.

Atilmotin is a selective motilin receptor agonist with a pKd value of 8.94. It enhances gastrointestinal motility by increasing lower esophageal sphincter (LES) and gastric pressures, making it a valuable tool for studying esophageal and gastric motility. This compound is particularly relevant for research applications focused on gastrointestinal disorders and the development of prokinetic agents.

RWJ-68022 is a cyclopentene derivative that acts as a motilin receptor antagonist. It effectively competes with motilin and erythromycin for binding to the motilin receptor site. This compound is valuable in research related to gastrointestinal disorders, providing insights into motilin's role in digestive physiology and its potential therapeutic applications.